RANI
Rani Therapeutics Holdings, Inc.
Biotechnology
Market Cap$22M
5Y Perf.-91.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RANI vs NUVL
Revenue, margins, valuation, and 5-year total return — side by side.
NUVL
Nuvalent, Inc.
Biotechnology
Market Cap$7.53B
5Y Perf.+476.9%
RANI vs NUVL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RANI | NUVL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $22M | $7.53B |
| Revenue (TTM) | $1M | $0.00 |
| Net Income (TTM) | $-28M | $-450M |
| Gross Margin | 100.0% | — |
| Operating Margin | -37.3% | — |
| Total Debt | $30M | $0.00 |
| Cash & Equiv. | $4M | $262M |
RANI vs NUVL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RANI
NUVL
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Rani Therapeutics H… (RANI) | 100 | 8.8 | -91.2% |
| Nuvalent, Inc. (NUVL) | 100 | 576.9 | +476.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RANI vs NUVL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NUVL leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
RANI
Rani Therapeutics Holdings, Inc.
The Growth Play
RANI is the clearest fit if your priority is growth exposure.
- EPS growth 21.1%, 3Y rev CAGR -27.7%
Best for: growth exposure
NUVL
Nuvalent, Inc.
The Income Pick
NUVL carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.09
- 446.1% 10Y total return vs RANI's -91.5%
- Lower volatility, beta 1.09, current ratio 15.27x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NUVL | 1.1% revenue growth vs RANI's -0.6% |
| Quality / Margins | NUVL | 3.2% margin vs RANI's -23.6% |
| Stability / Safety | NUVL | Beta 1.09 vs RANI's 2.22 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NUVL | +53.5% vs RANI's +11.1% |
| Efficiency (ROA) | NUVL | -37.8% ROA vs RANI's -279.3%, ROIC -32.5% vs -101.1% |
RANI vs NUVL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNUVLLAGGINGRANI
RANIRani Therapeutics Hol…
1leads
NUVLNuvalent, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs RANIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RANI1/1
Valuation MetricsMultiples, price ratios, and targets
NUVL2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NUVL6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
NUVL6/6
Risk & VolatilityBeta, volatility, and downside exposure
NUVL2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RANI leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RANI and NUVL operate at a comparable scale, with $1M and $0 in trailing revenue.
| Metric | RANIRani Therapeutics… | NUVLNuvalent, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $1M | $0 |
| EBITDAEarnings before interest/tax | -$44M | -$346M |
| Net IncomeAfter-tax profit | -$28M | -$450M |
| Free Cash FlowCash after capex | -$28M | -$313M |
| Gross MarginGross profit ÷ Revenue | +100.0% | — |
| Operating MarginEBIT ÷ Revenue | -37.3% | — |
| Net MarginNet income ÷ Revenue | -23.6% | — |
| FCF MarginFCF ÷ Revenue | -23.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +50.0% | -17.8% |
RANI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
NUVL leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | RANIRani Therapeutics… | NUVLNuvalent, Inc. |
|---|---|---|
| Market CapShares × price | $22M | $7.5B |
| Enterprise ValueMkt cap + debt − cash | $48M | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.89x | -17.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 21.71x | — |
| Price / BookPrice ÷ Book value/share | 7.59x | 5.96x |
| Price / FCFMarket cap ÷ FCF | — | — |
NUVL leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
NUVL leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
NUVL delivers a -42.8% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-2 for RANI. On the Piotroski fundamental quality scale (0–9), RANI scores 2/9 vs NUVL's 1/9, reflecting mixed financial health.
| Metric | RANIRani Therapeutics… | NUVLNuvalent, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.1% | -42.8% |
| ROA (TTM)Return on assets | -2.8% | -37.8% |
| ROICReturn on invested capital | -101.1% | -32.5% |
| ROCEReturn on capital employed | -159.9% | -34.4% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | 8.51x | — |
| Net DebtTotal debt minus cash | $26M | -$262M |
| Cash & Equiv.Liquid assets | $4M | $262M |
| Total DebtShort + long-term debt | $30M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -11.97x | -26.85x |
NUVL leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
NUVL leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NUVL five years ago would be worth $54,613 today (with dividends reinvested), compared to $846 for RANI. Over the past 12 months, NUVL leads with a +53.5% total return vs RANI's +11.1%. The 3-year compound annual growth rate (CAGR) favors NUVL at 39.5% vs RANI's -39.9% — a key indicator of consistent wealth creation.
| Metric | RANIRani Therapeutics… | NUVLNuvalent, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -31.5% | +1.5% |
| 1-Year ReturnPast 12 months | +11.1% | +53.5% |
| 3-Year ReturnCumulative with dividends | -78.2% | +171.2% |
| 5-Year ReturnCumulative with dividends | -91.5% | +446.1% |
| 10-Year ReturnCumulative with dividends | -91.5% | +446.1% |
| CAGR (3Y)Annualised 3-year return | -39.9% | +39.5% |
NUVL leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
NUVL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NUVL is the less volatile stock with a 1.09 beta — it tends to amplify market swings less than RANI's 2.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NUVL currently trades 90.6% from its 52-week high vs RANI's 24.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RANIRani Therapeutics… | NUVLNuvalent, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.38x | 1.01x |
| 52-Week HighHighest price in past year | $3.87 | $113.02 |
| 52-Week LowLowest price in past year | $0.39 | $63.56 |
| % of 52W HighCurrent price vs 52-week peak | +24.1% | +90.6% |
| RSI (14)Momentum oscillator 0–100 | 52.0 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 544K |
NUVL leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RANI as "Buy" and NUVL as "Buy". Consensus price targets imply 1583.1% upside for RANI (target: $16) vs 41.0% for NUVL (target: $144).
| Metric | RANIRani Therapeutics… | NUVLNuvalent, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $15.67 | $144.40 |
| # AnalystsCovering analysts | 7 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NUVL leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). RANI leads in 1 (Income & Cash Flow).
Best OverallNuvalent, Inc. (NUVL)Leads 4 of 6 categories
Loading custom metrics...
RANI vs NUVL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RANI or NUVL a better buy right now?
Analysts rate Rani Therapeutics Holdings, Inc.
(RANI) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RANI or NUVL?
Over the past 5 years, Nuvalent, Inc.
(NUVL) delivered a total return of +446. 1%, compared to -91. 5% for Rani Therapeutics Holdings, Inc. (RANI). Over 10 years, the gap is even starker: NUVL returned +461. 5% versus RANI's -91. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RANI or NUVL?
By beta (market sensitivity over 5 years), Nuvalent, Inc.
(NUVL) is the lower-risk stock at 1. 01β versus Rani Therapeutics Holdings, Inc. 's 2. 38β — meaning RANI is approximately 135% more volatile than NUVL relative to the S&P 500.
04Which is growing faster — RANI or NUVL?
On earnings-per-share growth, the picture is similar: Rani Therapeutics Holdings, Inc.
grew EPS 21. 1% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RANI or NUVL?
Nuvalent, Inc.
(NUVL) is the more profitable company, earning 0. 0% net margin versus -29. 2% for Rani Therapeutics Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUVL leads at 0. 0% versus -51. 9% for RANI. At the gross margin level — before operating expenses — RANI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RANI or NUVL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RANI or NUVL better for a retirement portfolio?
For long-horizon retirement investors, Nuvalent, Inc.
(NUVL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 01), +461. 5% 10Y return). Rani Therapeutics Holdings, Inc. (RANI) carries a higher beta of 2. 38 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NUVL: +461. 5%, RANI: -91. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RANI and NUVL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.